GuidelineThoracic cancer2018
Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 edition.
Guideline in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Immediate post-microwave ablation computed tomography model may better predict short-term response of stage I non-small cell lung cancer.World journal of radiology · 2026Article
- Evaluating the early therapeutic response of radiofrequency ablation in rabbit VX2 lung tumors: a comparison of four diffusion weighted imaging models.Translational lung cancer research · 2026Article
- Long-term clinical outcome of lung radiofrequency ablation in patients with musculoskeletal sarcoma.International journal of clinical oncology · 2026Article
- Risk factors and immune landscape of early local tumor progression after microwave ablation for lung cancer: a retrospective nested case-control study.Frontiers in immunology · 2026Article
- Application of Deep Learning for Real-Time Ablation Zone Measurement in Ultrasound Imaging.Cancers · 2024Article
- Chinese expert consensus on cone-beam CT-guided diagnosis, localization and treatment for pulmonary nodules.Thoracic cancer · 2024Article
- Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study.Thoracic cancer · 2022Article
- Comparison of clinical outcomes between cone beam CT-guided thermal ablation and helical tomotherapy in pulmonary metastases from hepatocellular carcinoma.Frontiers in oncology · 2022Article
- [Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- Advances in study of the sequence of lung tumor biopsy and thermal ablation.Thoracic cancer · 2021Review
- Assessment and Prognostic Value of Immediate Changes in Post-Ablation Intratumor Density Heterogeneity of Pulmonary TumorsFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 18 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer ranks first in incidence and mortality in China. Surgery is the primary method to cure cancer, but only 20-30% of patients are eligible for curative resection. In recent years, in addition to surgery, other local therapies have been developed for patients with numerous localized primary and metastatic pulmonary tumors, including stereotactic body radiation therapy and thermal ablative therapies through percutaneously inserted applicators. Percutaneous thermal ablation of pulmonary tumors is minimally invasive, conformal, repeatable, feasible, cheap, has a shorter recovery time, and offers reduced morbidity and mortality. Radiofrequency ablation (RFA), the most commonly used thermal ablation technique, has a reported 80-90% rate of complete ablation, with the best results obtained in tumors < 3 cm in diameter. Because the clinical efficacy of RFA of pulmonary tumors has not yet been determined, this clinical guideline describes the techniques used in the treatment of localized primary and metastatic pulmonary tumors in nonsurgical candidates, including mechanism of action, devices, indications, techniques, potential complications, clinical outcomes, post-ablation surveillance, and use in combination with other therapies. In the future, the role of RFA in the treatment of localized pulmonary tumors should ultimately be determined by evidence from prospective randomized controlled trials comparing sublobar resection or stereotactic body radiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.